Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission

PHASE3CompletedINTERVENTIONAL
Enrollment

3,408

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2009

Study Completion Date

March 31, 2010

Conditions
HIV InfectionHerpes Simplex, GenitalSexually Transmitted Diseases
Interventions
DRUG

Generic acyclovir

400 mg twice-daily oral

DRUG

Placebo

twice-daily oral

Trial Locations (13)

Unknown

Botswana-Harvard Partnership, Gabarone

Moi University - Indiana University, Eldoret

Kemri - Ucsf, Kisumu

University of Nairobi, Nairobi

Partners Study Thika Site, Thika

Projet San Francisco-Emory University, Kigali

University of Cape Town, Cape Town

Perinatal HIV Research Unit, University of Witswatersrand, Johannesburg

Reproductive Health and HIV Research Unit, Johannesburg

Kilimanjaro Christian Medical College-Harvard University, Moshi

Mulago Hospital - IDI, Kampala

Zambia-Emory HIV Research Project, Lusaka

Zambia-Emory HIV Research Project, Ndola/Kitwe

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of Washington

OTHER

NCT00194519 - Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission | Biotech Hunter | Biotech Hunter